Physician profile
John Curtis Tuttle
NPI 1194712877
$15,768.13
in general payments reported to CMS, 2019-2025
50 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,858 · 2020: $1,567 · 2021: $3,272 · 2022: $1,571 · 2023: $2,226 · 2024: $2,041 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,480 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,479.84 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $4,306.65 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,312.09 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,265.05 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,226.74 | 2021 | |
| Amgen INC. | $1,125.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $818.13 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $706.75 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $701.71 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $607.54 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $407.67 | 2019-2023 | |
| Astellas Pharma US INC | $331.02 | 2019-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $291.39 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.62 | 2020-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $195.41 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $184.12 | 2019-2024 | Verquvo, Gardasil 9, Capvaxive |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.